JCO invites you to enter our first Art of Oncology Narrative Medicine Contest for early career oncologists. Entries will be accepted through August 31, 2025. Finalists will be judged by a panel of ...

CD40 Ligand Blockade for Prevention of Graft-Versus-Host Disease This scoping review was conducted based on the Arksey and O'Malley framework and the work of Levac et al. The databases searched ...

This study evaluated three LLMs (GPT-3.5-turbo-0125, GPT-4-turbo, and GPT-4o) using drug names from HemOnc ontology. The assessment included 367 generic-to-brand and 2,516 brand-to-generic pairs, ...

Research suggests that a substantial proportion of those diagnosed with cancer may experience portions of their diagnosis and treatment as traumatic. 6 Additionally, many individuals diagnosed with ...

In the article that accompanies this editorial, Babiker et al 12 present the data that tumor-treating fields (TTFs) combined with gemcitabine plus nab-paclitaxel improved median overall survival ...

Older patients with classic Hodgkin lymphoma (cHL) have inferior survival compared with younger patients. We report a subset analysis of older patients (60 years and older) enrolled in the phase three ...

Podcasts JCO Oncology Practice Podcast. JCO OP: Put Into Practice highlights new research published in JCO OP related to cancer care delivery, quality, disparities, access. Host Dr. Fumiko Chino, MD ...

Deep Learning Model for Natural Language to Assess Effectiveness of Patients With Non–Muscle Invasive Bladder Cancer Receiving Intravesical Bacillus Calmette-Guérin Therapy Accurate identification of ...

The development of targeted therapeutics has revolutionized treatment for elderly patients with AML. Two doublet regimens are approved in the frontline setting for intensive chemotherapy ...

The article by Arnold et al titled “Outcomes of Adolescent and Young Adult Women With Breast Cancer in Rural and Urban Saskatchewan: A Retrospective Cohort Study” (J Glob Oncol 10.1200/GO-25-00018) ...

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate ...

Tumor-Treating Fields Open the Door to Progress for Patients With Locally Advanced Pancreatic Cancer We analyzed prospectively collected data from 442 patients with metastatic cutaneous melanoma who ...